Beneficial Effects of PKF275-055, a Novel, Selective, Orally Bioavailable, Long-Acting Dipeptidyl Peptidase IV Inhibitor in Streptozotocin-Induced Diabetic Peripheral Neuropathy
暂无分享,去创建一个
P. Ghezzi | G. Cavaletti | G. Lauria | I. Cervellini | R. Bianchi | N. Oggioni | C. Porretta-Serapiglia | B. Burkey | C. Porretta‐Serapiglia | Byan Burkey
[1] N. Calcutt,et al. GLP‐1 signals via ERK in peripheral nerve and prevents nerve dysfunction in diabetic mice , 2011, Diabetes, obesity & metabolism.
[2] K. Lee,et al. Neuroprotective effect of the glucagon‐like peptide‐1 receptor agonist, synthetic exendin‐4, in streptozotocin‐induced diabetic rats , 2011, British journal of pharmacology.
[3] E. Bosi. Time for testing incretin therapies in early type 1 diabetes? , 2010, The Journal of clinical endocrinology and metabolism.
[4] P. Whitton,et al. Glucagon‐like peptide 1 receptor stimulation as a means of neuroprotection , 2010, British journal of pharmacology.
[5] J. H. Park,et al. Effect of dipeptidyl peptidase-IV (DPP-IV) inhibitor (Vildagliptin) on peripheral nerves in streptozotocin-induced diabetic rats. , 2009, Archives of medical research.
[6] K. Takeuchi,et al. A novel dipeptidyl peptidase-4 inhibitor, alogliptin (SYR-322), is effective in diabetic rats with sulfonylurea-induced secondary failure. , 2009, Life sciences.
[7] S. Tesfaye. Advances in the management of diabetic peripheral neuropathy , 2009, Current opinion in supportive and palliative care.
[8] D. Drucker,et al. Incretin-based therapies for type 2 diabetes mellitus , 2009, Nature Reviews Endocrinology.
[9] B. Zinman,et al. Fifty‐two‐week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy , 2009, Diabetes, obesity & metabolism.
[10] T. Kern,et al. Sulfasalazine Blocks the Development of Tactile Allodynia in Diabetic Rats , 2008, Diabetes.
[11] D. Caruso,et al. Neuroprotective effects of dihydroprogesterone and progesterone in an experimental model of nerve crush injury , 2008, Neuroscience.
[12] M. Blandino-Rosano,et al. Anti-proliferative effect of pro-inflammatory cytokines in cultured beta cells is associated with extracellular signal-regulated kinase 1/2 pathway inhibition: protective role of glucagon-like peptide -1. , 2008, Journal of molecular endocrinology.
[13] K. Sugimoto,et al. Early changes in insulin receptor signaling and pain sensation in streptozotocin-induced diabetic neuropathy in rats. , 2008, The journal of pain : official journal of the American Pain Society.
[14] J. Foley,et al. The islet enhancer vildagliptin: mechanisms of improved glucose metabolism , 2008, International journal of clinical practice. Supplement.
[15] D. Drucker,et al. Biology of incretins: GLP-1 and GIP. , 2007, Gastroenterology.
[16] J. Holst,et al. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. , 2007, The Journal of clinical endocrinology and metabolism.
[17] N. Greig,et al. Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy , 2007, Experimental Neurology.
[18] G. Dienel,et al. Mechanical hyperalgesia correlates with insulin deficiency in normoglycemic streptozotocin-treated rats , 2006, Neurobiology of Disease.
[19] A. Barnett,et al. DPP‐4 inhibitors and their potential role in the management of type 2 diabetes , 2006, International journal of clinical practice.
[20] R. Pederson,et al. Applications of dipeptidyl peptidase IV inhibitors in diabetes mellitus. , 2006, The international journal of biochemistry & cell biology.
[21] D. Zochodne,et al. Remote neurotrophic support of epidermal nerve fibres in experimental diabetes , 2006, Diabetologia.
[22] P. Wang,et al. Acute and Chronic Effects of the Incretin Enhancer Vildagliptin in Insulin-Resistant Rats , 2005, Journal of Pharmacology and Experimental Therapeutics.
[23] J. Dupré. Glycaemic effects of incretins in Type 1 diabetes mellitus A concise review, with emphasis on studies in humans , 2005, Regulatory Peptides.
[24] D. Zochodne,et al. Direct insulin signaling of neurons reverses diabetic neuropathy. , 2004, Diabetes.
[25] N. Dang,et al. CD26/dipeptidyl peptidase IV: a regulator of immune function and a potential molecular target for therapy. , 2004, Current drug targets. Immune, endocrine and metabolic disorders.
[26] P. Ghezzi,et al. Erythropoietin both protects from and reverses experimental diabetic neuropathy. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[27] D. Pareyson,et al. Axonal swellings predict the degeneration of epidermal nerve fibers in painful neuropathies , 2003, Neurology.
[28] N. Calcutt,et al. Insulin prevents depolarization of the mitochondrial inner membrane in sensory neurons of type 1 diabetic rats in the presence of sustained hyperglycemia. , 2003, Diabetes.
[29] T. Hughes,et al. 1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. , 2003, Journal of medicinal chemistry.
[30] C. Pierson,et al. Insulin Deficiency Rather than Hyperglycemia Accounts for Impaired Neurotrophic Responses and Nerve Fiber Regeneration in Type 1 Diabetic Neuropathy , 2003, Journal of neuropathology and experimental neurology.
[31] N. Calcutt,et al. Protection of Sensory Function and Antihyperalgesic Properties of a Prosaposin-derived Peptide in Diabetic Rats , 2000, Anesthesiology.
[32] M. Malcangio,et al. A pharmacologic analysis of mechanical hyperalgesia in streptozotocin/diabetic rats , 1998, Pain.
[33] Andrew N. Rowan. Guide for the Care and Use of Laboratory Animals , 1996 .
[34] T. Wolfle. Institute of Laboratory Animal Resources. , 1995 .
[35] E. Scarpini,et al. Decrease of nerve Na+,K+-ATPase activity in the pathogenesis of human diabetic neuropathy , 1993, Journal of the Neurological Sciences.
[36] A. Eschalier,et al. Streptozocin-induced diabetic rats: behavioural evidence for a model of chronic pain , 1993, Pain.
[37] 姫野 龍仁. Beneficial effects of exendin-4 on experimental polyneuropathy in diabetic mice , 2011 .
[38] R. Pederson,et al. Dipeptidyl peptidase IV inhibition in animal models of diabetes. , 2003, Advances in experimental medicine and biology.
[39] M. Ko,et al. Evaluation of Annuloaortic Ectasia by Angioscopy and IVUS “Report of 2 cases” , 2000, Diagnostic and therapeutic endoscopy.
[40] J. Eichberg,et al. Effects of hypoxia and severity of diabetes on Na,K-ATPase activity and arachidonoyl-containing glycerophospholipid molecular species in nerve from streptozotocin diabetic rats. , 1997, Journal of the peripheral nervous system : JPNS.